Welcome to CDC stacks | Lyme disease surveillance summary volume 4, no. 2, March 1993 - 58085 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Lyme disease surveillance summary volume 4, no. 2, March 1993
Filetype[PDF-6.13 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Lyme disease surveillance summary volume 4, no. 2, March 1993
Details:
  • Description:
    Two items are presented in this issue of the Lyme Disease Surveillance Summary, an interim progress report on CDC funded Cooperative Agreements for research and education on Lyme disease, and the reprint of a recent article published in the MMWR on complications of treatment of suspected Lyme disease.

    The CDC Cooperative Agreements on Lyme disease are in the final year of a 3-year cycle. It is anticipated that Congress will consider appropriation of funds for a second cycle of Cooperative Agreements to begin in FY 94. If new funding is appropriated, CDC will make efforts to have a Request for Proposal (RFP) announcement published in the Federal Register by October 1993 so that awards can be made by April 1, 1994. The timing of the RFP announcement will be published in the Lyme Disease Surveillance Summary. CDC is pleased with the progress of Cooperative Agreement projects funded to date and looks forward to a continuation of this program.

    The study on adverse consequences of ceftriaxone treatment of suspected Lyme disease patients in New Jersey was initiated as a follow-up of a community-based study of Lyme disease in children conducted by CDC and the New Jersey Department of Health in Monmouth and Ocean Counties in June of 1992. The conclusions of that study highlighted the need to do studies of hospitalized patients, including a study of possible adverse consequences of intravenous antibiotic therapy.

  • Document Type:
  • Place as Subject:
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: